Form 4: Skye Bioscience Director Sells Shares to Cover Tax Obligations

A Skye Bioscience director, Paul A. Grayson, sold shares to cover tax obligations related to the vesting of performance-based restricted stock units.

Summary

• Paul A. Grayson, a director at Skye Bioscience, Inc., sold a total of 86,551 shares of common stock.
• The sales were executed on November 15, 2024, and November 18, 2024.
• The first sale involved 307 shares at a price of $5.55 per share.
• The second sale involved 86,244 shares at a weighted average price of $4.99 per share, with individual transactions ranging from $4.98 to $5.08.
• These sales were made to cover tax obligations arising from the vesting of performance-based restricted stock units.
• Following these transactions, Mr. Grayson beneficially owns 259,701 shares of Skye Bioscience common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing a director's stock sales for tax purposes. It doesn't indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It does not indicate any specific trend in the industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The sale of shares to cover tax obligations is a common practice among executives and directors who receive equity compensation.
• There are no specific industry benchmarks to compare this transaction to, as it is specific to the individual's tax situation and equity holdings.

Stakeholder Impact

• The share sales may have a minor impact on the stock price, but it is unlikely to be significant given the relatively small volume of shares sold compared to the total outstanding shares.

Key Dates

Keywords

Skye Bioscience, insider trading, stock sale, Form 4, director, tax obligations, restricted stock units, share sale